Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals (NASDAQ: ELDN ) completed enrollment of its phase 2 BESTOW trial using its immunosuppressive drug tegoprubart for the prevention of organ rejection in patients who undergo kidney transplant. Why should investors care about thisHe is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to he ...